News
A viral assembly inhibitor blocks SARSCoV-2 replication in airway epithelial cells, Communications Biology, 2024
Click here to read the full article.
A Pan-Respiratory Antiviral Chemotype Targeting a Transient Host Multi-Protein Complex, Open Biology, 2024
Click here for the full article.
Prosetta’s Oncology Program Wins ARPA-H Dash to Accelerate Health Outcomes Contest
After 6 rounds of voting, Prosetta’s submission to the ARPA-H Dash to Accelerate Health Outcomes, “One Drug for All Cancers” based on our Oncology Program emerges as the champion! Dr. Renee Wegrzyn, Head of ARPA-H, makes the announcement here.
Prosetta featured on #TalkPolymath podcast
As part of the ARPA-H Dash to Accelerate Heath Outcomes, Anuradha Lingappa, esq. from Prosetta makes an appearance on the #TalkPolymath Podcast to explain about our oncology program and how it feels to make it into the semifinals. Click here to watch the video about the other contestants and their technology, or skip to 32 minutes in to hear about Prosetta’s idea.
Oxidized MIF is an Alzheimer’s Disease drug target relaying external risk factors to tau pathology
Click here for the full article.
Prosetta in the Scripps Research Institutes NIH-funded Center for Pandemic Preparedness
Prosetta Biosciences is the only biotechnology company in the Scripps Research Institute’s NIH-funded Center for Pandemic Preparedness.
Click here for more details.
Small molecule assembly modulators with Pan-Cancer therapeutic efficacy
Preprint of Prosetta’s Oncology Manuscript, “Small Molecule Assembly Modulators with Pan-Cancer Therapeutic Efficacy” Available on Biorxiv. Click here for the full article.
Small Molecules That Modulate Protein Assembly as a Game-Changing Strategy for the Cancer Moonshot
Prosetta’s oncology program was featured in the Cancer Moonshot issue of the Life Sciences Insights magazine.
Click here for the full article (page 32).
Host–rabies virus protein–protein interactions as druggable antiviral targets
Click here for the full article.
Lingappa UF, Wu X, Macieik A, Yu SF, Atuegbu A, Corpuz M, Francis J, Nichols C, Calayag A, Shi H, Ellison JA, Harrell EK, Asundi V, Lingappa JR, Prasad MD, Lipkin WI, Dey D, Hurt CR, Lingappa VR, Hansen WJ, Rupprecht CE. Host-rabies virus protein-protein interactions as druggable antiviral targets. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E861-8. doi: 10.1073/pnas.1210198110. Epub 2013 Feb 12. PMID: 23404707; PMCID: PMC3593902.
Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals
Click here for the full article.
Broce S, Hensley L, Sato T, Lehrer-Graiwer J, Essrich C, Edwards KJ, Pajda J, Davis CJ, Bhadresh R, Hurt CR, Freeman B, Lingappa VR, Kelleher CA, Karpuj MV. Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals. Biol Direct. 2016 May 14;11:25. doi: 10.1186/s13062-016-0126-5. PMID: 27179769; PMCID: PMC4867995.
Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling
Click here for the full article.
Galli LM, Zebarjadi N, Li L, Lingappa VR, Burrus LW. Divergent effects of Porcupine and Wntless on WNT1 trafficking, secretion, and signaling. Exp Cell Res. 2016 Sep 10;347(1):171-183. doi: 10.1016/j.yexcr.2016.07.028. Epub 2016 Aug 1. PMID: 27492485; PMCID: PMC5032901.
Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation
Click here for the full article.
Marreiros R, Müller-Schiffmann A, Trossbach SV, Prikulis I, Hänsch S, Weidtkamp-Peters S, Moreira AR, Sahu S, Soloviev I, Selvarajah S, Lingappa VR, Korth C. Disruption of cellular proteostasis by H1N1 influenza A virus causes α-synuclein aggregation. Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6741-6751. doi: 10.1073/pnas.1906466117. Epub 2020 Mar 9. PMID: 32152117; PMCID: PMC7104400.
Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs-First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor
Click here for the full article.
Lingappa JR, Lingappa VR, Reed JC. Addressing Antiretroviral Drug Resistance with Host-Targeting Drugs-First Steps towards Developing a Host-Targeting HIV-1 Assembly Inhibitor. Viruses. 2021 Mar 10;13(3):451. doi: 10.3390/v13030451. PMID: 33802145; PMCID: PMC8001593.
Viruses as ‘Truffle Hounds’: Molecular Tools for Untangling Brain Cellular Pathology
Click here for the full article.
Müller-Schiffmann A, Trossbach SV, Lingappa VR, Korth C. Viruses as 'Truffle Hounds': Molecular Tools for Untangling Brain Cellular Pathology. Trends Neurosci. 2021 May;44(5):352-365. doi: 10.1016/j.tins.2020.11.004. Epub 2020 Dec 11. PMID: 33317827.
Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly
Click here for the full article.
Reed JC, Solas D, Kitaygorodskyy A, Freeman B, Ressler DTB, Phuong DJ, Swain JV, Matlack K, Hurt CR, Lingappa VR, Lingappa JR. Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly. J Virol. 2021 Jan 13;95(3):e00883-20. doi: 10.1128/JVI.00883-20. PMID: 33148797; PMCID: PMC7925099.
New methylene blue derivatives suggest novel anti-orthopoxviral strategies
Click here for the full article
Priyamvada L, Burgado J, Baker-Wagner M, Kitaygorodskyy A, Olson V, Lingappa VR, Satheshkumar PS. New methylene blue derivatives suggest novel anti-orthopoxviral strategies. Antiviral Res. 2021 Jul;191:105086. doi: 10.1016/j.antiviral.2021.105086. Epub 2021 May 13. PMID: 33992710.
Prosetta Host-targeted Pan-respiratory antiviral therapeutics manuscript now on Biorxiv
See www.biorxiv.org for the full article.
Click here for a nontechnical summary of the program.